John Parkinson

GSK’s bepirovirsen received this designation, and the company has its sights on the therapy potentially providing a functional cure for the millions of people around the world who are affected by this form of viral hepatitis.

The self-amplifying mRNA vaccine, ARCT-154, had an extended response compared to the BNT162b2 vaccine and was approved in Japan back in November.

The outbreak has seen 2 deaths and 23 hospitalizations across 11 states.

Phase 2 study for the investigational antiviral, ZSP1273 (onradivir), demonstrated safety and efficacy in reducing the time to resolution of symptoms in a multicenter trial.

The fungal infection includes 4 patients, but so far no deaths are associated with it.

This news comes after the World Health Organization (WHO) recently granted the vaccine an emergency use listing (EUL), and continues to become available to more countries.

The latest data on sexually transmitted infections (STI) shows a large increase in syphilis incidence rates year-over year, where others were either flat or saw a slight decrease. The report also shows an ongoing rise of syphilis cases over the long-term.

Investigators looked at potential risk factors as incidence rates changed over time after the introduction of COVID-19 and whether race and other variables affected the potential development of these infections.

The National Foundation for Infectious Diseases (NFID) medical director weighs in on this year’s respiratory virus season and offers some strategies to prevent transmission.

With the addition of live biotherapeutic products, a provider offers some insights into delivery and treatment considerations.

A small study offers some more information as to potential biomarkers for the ailment and may provide a better understanding of its path to potential treatments.

Atea Pharmaceuticals announced topline data from their phase 2 trial showing a higher than expected efficacy for the study.

How the development of antimicrobial stewardship programs can be an effective strategy for beginning to reduce this critical timing for patients in ICUs.

The city’s health department posted a statement on the recent events, and a new JAMA commentary from FDA leadership reminds the public that vaccine preventable diseases remain a health threat.

The panel discusses the importance of discussing the immunizations with patients now, as well as the value of them in future seasons.

A study used real-world CDC data to calculate the number of people who needed to be vaccinated to prevent both medical events in the greater community.

Biopharmaceutical company, Invivyd, made the request to the FDA for its investigational antibody, VYD222.

New and novel antimicrobials remain at a crossroads as the path to development and economic viability continue to be serious challenges. Our Editor-in-Chief weighs in on this topic and some of the other most significant ones from this past year.

The current treatment pathway might need to evolve to adjust to rapid diagnostics and narrowing down the antibiotics to aid in optimal outcomes for sicker patients with gram-negative infections.

The first self-amplifying mRNA COVID-19 vaccine was approved in Japan; how email reminders fared in encouraging people with diabetes to get their influenza vaccines; in the latest RSV Roundtable, our panel discusses the addition of nirsevimab; and a biotech company is focused on the detection and diagnosis of viral diseases, with a particular interest in Long COVID.

United Kingdom-based Virax Biolabs is a biotech company that is focused on the detection and diagnosis of viral diseases, with a particular interest in the enigmatic, Long COVID.

Early treatment of the antiviral tecovirimat (TPOXX) could inhibit virus replication by more than 90%.

The company’s investigational V116 vaccine covers 21 serotypes, and if approved, it would be the first pneumococcal conjugate vaccine specifically designed for adults.

The 2 recalls were performed due to concerns about salmonella in the former and lead in the latter.

The ARCT-154 vaccine from CSL and Arcturus Therapeutics was approved in adults.

In the news this week, the FDA approved the antifungal, isavuconazonium sulfate, which is indicated for children as young as 1 year of age; the continued clinical usefulness of doxycycline; examining infectious disease consults in gram-negative bacteremia; and a clinician utilizes mobile clinics to bring care to marginalized populations.

A study finds pathogen spores remain on surgical scrubs and patient gowns even after sodium hypochlorite disinfectant application. This finding presents an infection prevention challenge.

A clinician utilizes mobile clinics to bring a hybrid of primary and urgent care to marginalized populations and help people overcome barriers and gets them into the continuum of care.

The older antibiotic has been shown to be effective as a preventative measure for one group of infections as well as reducing the risk of a health care-associated infection.

The approval of the antifungal, isavuconazonium sulfate (Cresemba), is indicated for children as young as 1 year of age and the approval was based from 2 clinical trials.